Enabling pre-clinical program of NEW Chemical Entities (NCEs) and providing one stop solution to customize the product in rapid phase. The activities recorded in the electronic lab notebook enforces online documentation in accordance to principles of ALCOA+. Our value proposition: Discovery Research Quick access to the building blocks and key intermediates Time is essence of synthesis Enable the supply for discovery research 100g to few kilos
Early phase development Quick access to Drug substance for toxicology studies Phase appropriate PRD to enable the scale up Non GMP facility: Flexible operation and accelerated delivery
Infrastructure
- 300+ fume hoods
- Kilo lab with cylindrical reactor varying 5L to 50L capacity
- Reactors from 500 L to 5000 L in Hyderabad & Bangalore
- 50L autoclave a with 20kg/Cm2 design pressure
- Pressure Nutsche filter, vaccum tray dryer and 20L rotavapor for downstream process
- Huber unit to operate the process -20 to 150 degree Celsius
- Internal network of strategic business partners
- We also have a potent kilo lab
Scientific Expertise
- Qualified PhDs and Postdocs in organic chemistry
- 150+ scientists in chemistry and analytical services
- 10+ process engineers and process safety engineers
Chemistry Capabilities
Expertise in
- Metal promoted cross coupling reaction
- Halogenation reactions
- High pressure hydrogenation
- Metal hydrate reactions
- Carbohydrates
- Lipids
- Peptides
- PEGylation
- Asymmetric synthesis
- Deuterated compound
- Heterocyclic chemistry
- Asymmetric hydrogenation
- Chiral synthesis
Analytical Capability
- High-performance liquid chromatography with varying detectors
- Gas chromatography
- Mass triple quad, 1H NMR Bruker
- Differential scanning calorimeter
- Micro calorimeter
- Reaction calorimetry
Why Aurigene Pharmaceutical Services?
Quick turnaround of sample delivery
A strong scientific and analytical team
Infrastructure for mg to kg synthesis
Large network of qualified strategic business partners
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Development and Kilo Lab
Contact Us
Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...
Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...
Read More
Technology meets sustainability - How a complex API development process goes green
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...
Read MoreAlternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2023
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2021
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2021
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More -
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
2021
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.